Transforaminal lumbar interbody fusion with rhBMP-2 in spinal deformity, spondylolisthesis, and degenerative disease - Part 2: BMP dosage-related complications and long-term outcomes in 509 patients

Spine

Volumn 38, Issue 13, 2013, Pages 1137-1145

  Crandall, Dennis G ^a,b   Revella, Jan ^c   Patterson, Jason ^b   Huish, Eric ^c   Chang, Michael ^a,b   McLemore, Ryan ^b  

^a Sonoran Spine Center   (United States)

^b Banner Good Samaritan Orthopaedic Residency Program   (United States)

^c Sonoran Spine Research and Education Foundation   (United States)

Author keywords

BMP; Complications; Degenerative disc disease; Ectopic bone; Scoliosis; Seroma; Spondylolisthesis; Transforaminal lumbar interbody fusion (TLIF)

Indexed keywords

RECOMBINANT BONE MORPHOGENETIC PROTEIN 2;

ADULT; AGED; ARTICLE; BONE GROWTH; DEEP VEIN THROMBOSIS; DEGENERATIVE DISEASE; FOLLOW UP; HEART ARREST; HUMAN; INTESTINE OBSTRUCTION; LUNG EMBOLISM; MAJOR CLINICAL STUDY; NEUROLOGIC DISEASE; PRIORITY JOURNAL; PSEUDARTHROSIS; SEROMA; SMOKING; SPINE FUSION; SPINE MALFORMATION; SPONDYLOLISTHESIS; TRANSFORAMINAL LUMBAR INTERBODY FUSION; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BONE MORPHOGENETIC PROTEIN 2; BONE SCREWS; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERVERTEBRAL DISC DEGENERATION; LOGISTIC MODELS; LUMBAR VERTEBRAE; MALE; MIDDLE AGED; PAIN MEASUREMENT; PAIN, POSTOPERATIVE; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; SPINAL DISEASES; SPINAL FUSION; SPONDYLOLISTHESIS; TIME FACTORS; TRANSFORMING GROWTH FACTOR BETA; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84879080440     PISSN: 03622436     EISSN: 15281159     Source Type: Journal    
DOI: 10.1097/BRS.0b013e3182880298     Document Type: Article

References (43)

1. Williams B, Smith J, Kai-Ming G, et al. Does bone morphogenetic protein increase the incidence of perioperative complications in spinal fusion? A comparison of 55,862 cases of spinal fusion with and without bone morphogenetic protein. Spine 2011; 36: 1685-91.
2. Ong K, Villarraga M, Lau E, et al. Off-label use of bone morphogenetic proteins in the United States using administrative data. Spine 2010; 35: 1794-800.
3. Rihn J, Makda J, Hong J, et al. The use of RhBMP-2 in single-level transforaminal lumbar interbody fusion: a clinical and radiographic analysis. Eur Spine J 2009; 18: 1629-36.
4. Mummaneni P, Pan J, Haid R, et al. Contribution of recombinant human bone morphogenetic protein-2 to the rapid creation of interbody fusion when used in transforaminal lumbar interbody fusion: a preliminary report. J Neurosurg (Spine 1) 2004; 1: 19-23.
5. Park P, Foley K. Minimally invasive transforaminal lumbar interbody fusion with reduction of spondylolisthesis: technique and outcomes after a minimum of 2 years follow-up. Neurosurg Focus 2008; 25: E16.
6. Schwender J, Holly L, Rouben D, et al. Minimally invasive transforaminal lumbar interbody fusion (TLIF): technical feasibility and initial results. J spinal Dis Tech 2005; 18: S1-6.
7. Vaidya R. Transforaminal interbody fusion and the off-label use of recombinant human bone morphogenetic protein-2. Spine J 2009; 9: 667-9.
8. McClellan J, Mulconrey D, Forbes R, et al. Vertebral bone resorption after transforaminal lumbar interbody fusion with bone morphogenetic protein rhBMP-2. J Spinal Dis Tech 2006; 19: 483-6.
9. Rihn JA, Patel R, Makda J, et al. Complications associated with single-level transforaminal lumbar interbody fusion. Spine J 2009; 9: 623-9.
10. Helgeson M, Lehman R, Patzkowski J, et al. Adjacent vertebral body osteolysis with bone morphogenetic protein use in transforaminal lumbar interbody fusion. Spine J 2011; 11: 507-10.
11. Knox JB, Dai JM, III, Orchowski J. Osteolysis in transforaminal lumbar interbody fusion with bone morphogenetic protein-2. Spine 2011; 36: 672-6.
12. Lewandrowski K, Nanson C, Calderon R. Vertebral osteolysis after posterior interbody lumbar fusion with recombinant human bone morphogenetic protein 2: a report of five cases. Spine J 2007; 7: 609-14.
13. Wong D, Kumar A, Jatana S, et al. Neurologic impairment from ectopic bone in the lumbar canal: a potential complication of offlabel PLIF/TLIF use of bone morphogenetic protein-2 (BMP-2). Spine J 2008; 8: 1011-8.
14. Carragee E, Hurwitz E, Weiner B. A critical review of recombinant human bone morphogenetic protein-2 trials in spinal surgery: emerging safety concerns and lessons learned. Editorial. Spine J 2011; 11: 471-91.
15. Haid R, Branch C, Alexander J, et al. Posterior lumbar interbody fusion using recombinant human bone morphogenetic protein type 2 with cylindrical interbody cages. Spine J 2004; 4: 527-38.
16. Boden SD, Zdeblick TA, Sandhu HS, et al. The use of rhBMP-2 in interbody fusion cages. Definitive evidence of osteoinduction in humans: a preliminary report. Spine 2000; 25: 376-81.
17. Boden SC, Kang J, Sandhu H, et al. Use of recombinant human bone morphogenetic protein-2 to achieve posterolateral lumbar spine fusion in humans: a prospective, randomized clinical pilot trial. Spine 2002; 27: 2662-73.
18. Burkus JK, Gornet MF, Dickman CA, et al. Anterior lumbar interbody fusion using rhBMP-2 with tapered interbody cages. J Spinal Disord Tech 2002; 15: 337-49.
19. Burkus JK, Transfeldt EE, Kitchel SH, et al. Clinical and radiographic outcomes of anterior lumbar interbody fusion using recombinant human bone morphogenetic protein-2. Spine 2002; 27: 2396-408.
20. Baskin DS, Ryan P, Sonntag V, et al. A prospective, randomized, controlled cervical fusion study using recombinant human bone morphogenetic protein-2 with cornerstone-sr allograft ring and the atlantis anterior cervical plane. Spine 2003; 28: 1219-24.
21. Burkus JK, Sandhu HS, Gornet MF, et al. Use of rhBMP-2 in combination with structural cortical allografts surgery: clinical and radiographic outcomes in anterior lumbar spinal fusion. J Bone Joint Surg Am 2005; 87: 1205-12.
22. Burkus JK, Heim SE, Gornet MF, et al. Is infuse bone graft superior to autograft bone? An integrated analysis of clinical trials using the LT cage lumbar tapered fusion device. J Spinal Disord Tech 2003; 16: 113-32.
23. Boakye M, Mummaneni PV, Garrett M, et al. Anterior cervical discectomy and fusion involving a polyetheretherketone spacer and bone morphogenetic protein. J Neurosurg Spine 2005; 2: 521-5.
24. Glassman SD, Dimar JR, Burkus JK, et al. The efficacy of rhBMP-2 for posterolateral lumbar fusion in smokers. Spine 2007; 32: 1693-8.
25. Dimar JR, Glassman SD, Burkus JK, et al. Clinical and radiographic analysis of an optimized rhBMP-2 formulation as an autograft replacement in posterolateral lumbar spine arthrodesis. J Bone Joint Surg Am 2009; 91: 1377-86.
26. Dawson E, Bae HW, Burkus JK, et al. Recombinant human bone morphogenetic protein-2 on an absorbable collagen sponge with an osteoconductive bulking agent in posterolateral arthrodesis with instrumentation. A prospective randomized trial. J Bone Joint Surg Am 2009; 91: 1604-13.
27. Crandall D, Revella J, Patterson J, et al. Transforaminal lumbar interbody fusion with rhBMP-2 in spinal deformity and degenerative disease - part 1: large series diagnosis related outcomes and complications with 2-9 year follow-up. Spine. 2013; 38: 1128-36.
28. Barnes B, Rodts G, Haid R, et al. Allograft implants for posterior lumbar interbody fusion: results comparing cylindrical dowels and impacted wedges. Neurosurgery 2002; 51: 1191-7.
29. Okuda S, Miyauchi A, Oda T, et al. Surgical complications of posterior lumbar interbody fusion with total facetectomy in 251 patients. J Neurosurg Spine 2006; 4: 304-9.
30. Joseph V, Rampersaud Y. Heterotopic bone formation with the use of rhBMP-2 in posterior minimal access interbody fusion: a CT analysis. Spine 2007; 32: 2885-90.
31. Villavicencio A, Burneikiene S, Bulsara K, et al. Perioperative complications in transforaminal lumbar interbody fusion versus anterior-posterior reconstruction for lumbar disc degeneration and instability. J Spinal Dis Tech 2006, 19: 92-97.
32. Okuyama K, Abe E, Suzuki T, et al. Posterior lumbar interbody fusion: a retrospective study of complications after facet joint excision and pedicle screw fixation in 148 cases. Acta Orthop Scand 1999; 70: 329-34.
33. Hackenberg L, Halm H, Bullmann V, et al. Transforaminal lumbar interbody fusion: a safe technique with satisfactory three to five year results. Eur Spine J 2005; 14: 551-8.
34. Anand N, Hamilton JF, Perri B, et al. Cantilever TLIF with structural allograft and RhBMP2 for correction and maintenance of segmental sagittal lordosis: long-term clinical, radiographic, and functional outcome. Spine 2006; 31: E748-53.
35. Lanman TH, Hopkins TJ. Lumbar interbody fusion after treatment with recombinant human bone morphogenetic protein-2 added to 70:30 poly(L-lactide-co-D,L-lactide) bioresorbable implants. Neurosurg Focus 2004; 16: 1-4.
36. Meisel H, Schnoring M, Hohaus C, et al. Posterior lumbar interbody fusion using rhBMP-2. Eur Spine J 2008; 17: 1735-44.
37. Geibel PT, Boyd DL, Slabisak V. The use of recombinant human bone morphogenic protein in posterior interbody fusions of the lumbar spine. J Spine Dis Tech 2009; 22: 315-20.
38. Owens K, Glassman SD, Howard JM, et al. Perioperative complications with rhBMP-2 in transforaminal lumbar interbody fusion. Eur Spine J 2011; 20: 612-7.
39. Hoffmann MF, Jones CB, Sietsema DL. Adjuncts in posterior lumbar spine fusion: comparison of complications and efficacy. Arch Orthop Trauma Surg. 2012; 132: 1105-10.
40. Dmitriev A, Lehman R, Symes A. Bone morphogenetic protein-2 and spinal arthrodesis: the basic science perspective on protein interaction with the nervous system. Spine J 2011; 11: 500-5.
41. Poynton AR, Lane JM. Safety profile for the clinical use of bone morphogenetic proteins in the spine. Spine 2002; 27: S40-8.
42. Crandall DG, Revella J, Revella D, et al. The presence and distribution of leg pain after spine surgery: laminectomy vs. TLIF with BMP. Lumbar Spine Research Society Paper #8, 2012.
43. Toth J, Boden S, Burkus J, et al. Short-term osteoclastic activity induced by locally high concentrations of recombinant human bone morphogenetic protein-2 in a cancellous bone environment. Spine 2009; 34: 539-50.